Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
蒋学金发布了新的文献求助10
1秒前
源味小王发布了新的文献求助10
1秒前
snow发布了新的文献求助10
1秒前
刘旭阳完成签到,获得积分20
3秒前
小蜗牛发布了新的文献求助10
4秒前
duan发布了新的文献求助10
5秒前
6秒前
DW应助畅快的荣轩采纳,获得10
6秒前
雨姐科研发布了新的文献求助10
6秒前
ho完成签到,获得积分10
7秒前
正直静曼完成签到 ,获得积分10
9秒前
10秒前
夏雪儿发布了新的文献求助10
11秒前
11秒前
臣子完成签到,获得积分20
12秒前
12秒前
13秒前
Ditf完成签到,获得积分10
15秒前
15秒前
要减肥的鱼完成签到,获得积分20
18秒前
19秒前
20秒前
20秒前
老马发布了新的文献求助10
21秒前
22秒前
七听应助sssugar采纳,获得30
22秒前
汉堡包应助snow采纳,获得10
22秒前
super完成签到,获得积分10
22秒前
传奇3应助流萤采纳,获得10
23秒前
思源应助ZetaGundam采纳,获得10
23秒前
桥豆麻袋发布了新的文献求助10
23秒前
大模型应助蒋学金采纳,获得10
25秒前
sadsada发布了新的文献求助10
27秒前
阿六完成签到,获得积分10
27秒前
29秒前
打打应助王明卓采纳,获得10
31秒前
Lucas应助sadsada采纳,获得50
32秒前
科研通AI6.2应助你好采纳,获得10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Cardiovascular Research and Medicine(2e) 820
自動車の空力技術 800
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7781791
求助须知:如何正确求助?哪些是违规求助? 9321417
关于积分的说明 20382975
捐赠科研通 7369678
什么是DOI,文献DOI怎么找? 3320126
关于科研通互助平台的介绍 2467955
邀请新用户注册赠送积分活动 2336049